Hansoh Pharmaceutical (002412.SZ) released its performance for the first half of the year, with a net profit attributable to the parent company of 68.5384 million yuan, a decrease of 31.80%.

Zhitong Finance APP News, Hansen Pharmaceutical (002412.SZ) released its 2025 interim report, with the company's operating income reaching 509 million yuan, a year-on-year increase of 5.91%. The net profit attributable to shareholders of the listed company was 68.5384 million yuan, a year-on-year decrease of 31.80%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 64.7695 million yuan, a year-on-year decrease of 31.72%. The basic earnings per share was 0.1362 yuan.